.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,316,504

« Back to Dashboard

Details for Patent: 6,316,504

Title: Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
Abstract:The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.
Inventor(s): Youdim; Moussa B. H. (Tivon, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL)
Assignee: Technion Research and Development Foundation, Ltd. (Technion, IL) Teva Pharmaceuticals Industries, Ltd. (Jerusalem, IL)
Filing Date:Nov 16, 1998
Application Number:08/952,705
Claims:1. A method of treating multiple sclerosis in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat multiple sclerosis in the subject.

2. The method of claim 1, wherein the pharmaceutically acceptable salt of R(+)-N-propargyl-1 aminoindan is selected from the group consisting of:

the mesylate salt;

the esylate salt;

the sulfate salt; and

the hydrochloride salt.

3. The method of claim 2, wherein the pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan is the mesylate salt.

4. The method of claim 1, wherein the effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof to be administered is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject.

5. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously, orally, rectally, transdermally, or parenterally.

6. The method of claim 5, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered intravenously.

7. The method of claim 1, wherein the subject is human and the effective amount is from about 0.01 mg to 50.0 mg per day.

8. The method of claim 7, wherein the effective amount is from about 0.1 to 10.0 mg per day.

9. The method of claim 5, wherein the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered orally.

10. The method of claim 1, wherein the R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof is supplemented with a pharmaceutically acceptable carrier, which is a liquid; or a gel pharmaceutical.

11. The method of claim 10, wherein the amount of the salt of R(+)-N-propargyl-1-aminoindan administered is an amount from about 0.1 mg to about 100 mg.

12. The method of claim 11, wherein the amount of the salt of R(+)-N-propargyl-1-aminoindan administered is an amount from about 1 mg to about 10 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc